Novel Therapeutic Targets of Rheumatoid Arthritis

Dear Colleagues,

Rheumatoid arthritis is a common chronic inflammatory disease affecting approximately 20 million people worldwide, with a tremendous impact on the quality of life of patients and significant costs for healthcare systems and society at large. Importantly, there are no cures. The increased utilisation of single-cell and spatial RNAseq has revealed new immunological pathways, but it has also highlighted the complexity of disease pathogenesis and the poor specificity of currently available treatments. While novel therapies, including CAR-T cells, have recently been proposed for the treatment of patients with RA, there is an urgent need for targeted therapeutic interventions and the identification of prognostic markers of responses to treatment. Therefore, we would like to invite the submission of primary research and review articles that utilise, expand, and validate recently identified, or propose new, molecular pathways that can be targeted in the treatment of patients with RA.

Dr. Achilleas Floudas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• rheumatoid arthritis
• translational immunology
• transcriptomics
• novel therapeutic targets